{"prompt": "['For patients who require multiple doses of bypassing agents, laboratory monitoring should', 'be performed every 24-48 hours until 24-48 hours after the last dose of bypassing agents is', 'administered to treat a specific bleed. laboratory results which are required as', \"part of the patient's safety assessment should be recorded in the unscheduled visit eCRFs.\", '4.5.6.9', 'Sampling Procedures and Sample Storage, Shipment and Destruction', 'For sampling procedures, storage conditions, and shipment instructions, see the Central', 'Laboratory Services Manual.', 'HIV and hepatitis serology testing will be donc in the local laboratory at screening. All', 'women of childbearing potential (including those who have had a tubal ligation) will have a', 'serum pregnancy test at screening donc in the local laboratory and again within 7 days prior', 'to the first dose of emicizumab, if applicable. Urine pregnancy tests will be performed at', 'every clinic visit at the local laboratory, except for Weeks 2 and 3.', 'Plasma or serum samples, as applicable, collected for anti emicizumab antibody,anti', 'FVIII antibody, PD biomarker, safety biomarker, safety coagulation system biomarker,', 'and-bone and joint biomarker assessments and other future exploratory research will be', 'destroyed no later than 5 years after the final Clinical Study Report has been completed.', '4.5.7', 'Bleed Assessments', 'Patients will be trained on how to record their bleeds and hemophilia medication use using an ePRO', 'device where possible. When bleeds occur, patients will need to record the site of bleed, type of', 'bleed, time of each individual bleed (day, start and stop time), and treatment for bleed.', 'Patients will need to record whon they have bleods or hemophilia modication use, including', 'emicizumab, or at least every week.-At least once a week, patients will need to record any', 'hemophilia medication use (including emicizumab) and information regarding any bleeding events.', 'Investigator review of patient-reported bleed/medication records with the patient/caregiver', 'will occur for completeness and accuracy throughout the study.', '4.5.8', 'Surgical Events', 'Thorough documentation on surgical events will be requested, including type of surgery or', 'procedures, treatments, outcomes, etc.', '4.5.9', 'Patient-Reported Outcomes', 'The PRO questionnaire data will be collected to document the treatment benefit of', 'emicizumab. The questionnaires, translated into the local language as required, will be', 'completed in their entirety at specified timepoints during the study. To ensure instrument', 'validity and that data standards meet health authority requirements, questionnaires will be', 'self-administered before the patient/caregiver receives any information on disease status,', 'Emicizumab - F. Hoffmann-La Roche Ltd', '34 / Protocol MO39129, Version 3']['prior to the performance of non-PRO assessments, and prior to the administration of', 'emicizumab study treatment, unless otherwise specified.', '4.5.9.1', 'HRQoL Assessments', 'The Haem-A-Qol (version AU 3.0; UK English) and the Hemophilia Quality of Life Short Form', '(Haemo-QoL-SF) (version AU 2.0; uK English) will be completed electronically and used to', 'measure HRQoL in adults and adolescents, respectively-(see Appendix 3)', 'EmiPref Patient Preference Questionnaire', 'and Appendix 44', 'Clinical Criteria for Diagnosing Anaphylaxis', '7. Paper versions of the questionnaires are also available in case of ePRO outage or if an ePRO device', 'is otherwise unavailable.', '4.5.9.2', 'Health Status Assessments (EQ-5D-5L)', 'The EQ-5D-5L (version 2; UK English) (see Appendix 55', 'WHO Toxicity Grading Scale for Determining the Severity of Laboratory', 'Abnormalities and Adverse Events', 't is a generic, self-report, preference-based health utility measure that consists of six', 'questions that are completed electronically and is used to assess health status and inform', 'pharmacoeconomic evaluations. Paper versions of the questionnaires are also available in case of', 'ePRO outage or if an ePRO device is otherwise unavailable. The EQ-5D-5L consists of two', 'components. The first part, health state classification, contains five dimensions of health:', 'mobility, self-care, usual activities, pain / discomfort, and anxiety / depression (Herdman et al.', '2011; Janssen et al. 2013). Published weights are available that permit the creation of a', 'single summary score. Overall scores range from 0 to 1, with low scores representing a', 'higher level of dysfunction. The second part is a 0 to 100-point visual analog scale (VAS),', 'which assesses current health status and higher scores are reflective of better health.', '4.5.9.3', 'Treatment Preference Questionnaire', 'Patient preference will be assessed through a paper version of the EmiPref questionnaire', '(Appendix 3), which asks patients to specify the treatment they would prefer to continue to', 'receive after receiving treatment with their previous episodic or prophylactic regimen and SC', 'emicizumab. Patients who express a preference are then asked to identify the reasons', 'which may have influenced their decision and indicate the top three reasons for their choice.', 'Patients will complete this questionnaire after 3 months of treatment with emicizumab.', '4.6', 'PATIENT, TREATMENT, STUDY AND SITE DISCONTINUATION', 'A', 'Safety Follow up Visit will be conducted 24 weeks after last dose of emicizumab in', 'patients who discontinue emicizumab Patients who discontinue emicizumab prior to the', 'Emicizumab - F. Hoffmann-La Roche Ltd', '35 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}